FMS

BULLISH

$22.77 Live

Fresenius Medical Care AG · NYSE

Target $27.49 (+20.7%)

$20.95 52W Range $30.46

FMS Fresenius Medical Care AG - Fundamental Analysis

BULLISH

Console Chart News

FMS Stock | Fundamental Analysis & Investment Insights

NYSE • Healthcare • Medical Care Facilities

Current Price Live

$22.77

Analyst Target

$27.49

+20.7% Upside

52W High

$30.46

52W Low

$20.95

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 27, 2026

Market cap

$12.44B

P/E

11.56

ROE

7.9%

Profit margin

5.0%

Debt/Equity

0.76

Dividend yield

3.58%

AI Analysis

AI-powered fundamental assessment

Confidence

75%

FMS presents a classic deep-value opportunity, characterized by a stable Piotroski F-Score of 6/9 and a current price ($22.77) trading significantly below both its Graham Number ($35.27) and Intrinsic Value ($58.12). While top-line revenue growth is stagnant (-0.30%), the company has demonstrated a massive recovery in earnings and maintains a sustainable dividend payout ratio of 42.76%. The valuation is exceptionally attractive with a Forward P/E of 5.62 and a Price/Book of 0.81. However, the bullish value thesis is countered by a completely bearish technical trend and weak insider sentiment, suggesting a 'value trap' risk if revenue does not stabilize.

Key Strengths

Significant undervaluation relative to Graham Number and Intrinsic Value

Strong earnings recovery with YoY growth of 420%

Attractive valuation multiples (P/B 0.81, P/S 0.63, Forward P/E 5.62)

Stable financial health as indicated by a Piotroski F-Score of 6/9

Sustainable dividend yield (3.58%) with a conservative payout ratio

Key Risks

Stagnant revenue growth (-0.30% YoY) indicating a lack of top-line momentum

Severe bearish technical trend (0/100 score)

Low insider sentiment (40/100) suggesting lack of internal confidence

Low Return on Equity (7.93%) compared to historical healthcare benchmarks

Negative 5-year price performance (-34.1%)

AI Fair Value Estimate

Based on comprehensive analysis

$40.0

+75.7% above current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Strong

Value

Future

Past

Health

Dividend

AI Verdict

Deep Value Play

Key drivers: Extreme valuation discount, Earnings recovery, Stagnant revenue, Bearish technicals

Confidence

80%

Value

95/100

Ref P/E 11.56, PEG 0.76, Graham Number $35.27

Positives

Price well below Graham Number ($35.27)
P/B below 1.0
PEG ratio of 0.76

Watchpoints

Market continues to discount the stock

Future

50/100

Ref Revenue Growth -0.30%, Earnings Growth 420%

Positives

Massive EPS growth recovery

Watchpoints

Flat revenue growth
Low analyst target upside compared to intrinsic value

Past

30/100

Ref 5Y Change -34.1%

Positives

Recent quarterly earnings beats

Watchpoints

Poor 5-year return (-34.1%)
Consistent downward price pressure

Health

70/100

Ref Piotroski F-Score 6/9, Debt/Equity 0.76

Positives

Piotroski F-Score 6/9 (Stable)
Current Ratio 1.26

Watchpoints

Altman Z-Score unavailable for definitive distress check

Dividend

75/100

Ref Yield 3.58%, Payout 42.76%

Positives

Sustainable payout ratio (42.76%)
Consistent yield

Watchpoints

Yield is modest compared to high-risk value plays

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$22.77

Analyst Target

$27.49

Upside/Downside

+20.7%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for FMS and closest competitors.

Updated 2026-04-24

Company	5Y	3Y	1Y	6M	1M	1W
FMS Fresenius Medical Care AG Primary	-34.1%	+6.8%	-3.1%	-16.4%	+2.3%	-2.7%
IONS Ionis Pharmaceuticals, Inc. Peer	+83.9%	+101.9%	+181.4%	+7.4%	+0.5%	+0.5%
MDGL Madrigal Pharmaceuticals, Inc. Peer	+334.6%	+119.2%	+63.1%	+22.9%	+18.2%	-1.5%
ENSG The Ensign Group, Inc. Peer	+121.6%	+109.3%	+65.7%	+16.2%	-2.4%	+2.3%
JAZZ Jazz Pharmaceuticals plc Peer	+19.7%	+32.4%	+90.3%	+43.4%	+4.7%	+3.9%

FMS

Fresenius Medical Care AG

Primary

-34.1%

+6.8%

-3.1%

-16.4%

+2.3%

-2.7%

ION

Ionis Pharmaceuticals, Inc.

Peer

+83.9%

+101.9%

+181.4%

+7.4%

+0.5%

MDG

Madrigal Pharmaceuticals, Inc.

Peer

+334.6%

+119.2%

+63.1%

+22.9%

+18.2%

-1.5%

ENS

The Ensign Group, Inc.

Peer

+121.6%

+109.3%

+65.7%

+16.2%

-2.4%

+2.3%

JAZ

Jazz Pharmaceuticals plc

Peer

+19.7%

+32.4%

+90.3%

+43.4%

+4.7%

+3.9%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

11.56

5.62

0.76

0.81

0.63

0.84

6.25

$12.44B

Profitability

Profit margins and return metrics

Profit Margin 4.98%

Operating Margin 11.68%

Gross Margin 25.62%

ROE 7.93%

ROA 3.62%

Growth

Revenue and earnings growth rates

Revenue Growth -0.3%

Earnings Growth +420.0%

Q/Q Revenue Growth -0.3%

Q/Q Earnings Growth +388.9%

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

0.76

Moderate

Current Ratio

1.26

Good

Quick Ratio

0.85

Poor

Cash/Share

$6.23

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue

$5.1B

Gross Margin

27.4%

Op. Margin

10.8%

Net Margin

6.5%

Total Assets

$31.0B

Liabilities

$16.7B

Equity

$13.3B

Debt/Equity

1.26x

Operating CF

$1.0B

CapEx

$-0.4B

Free Cash Flow

$0.6B

FCF Yield

58%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-05

$N/A

2026-02-24

$0.72

+30.0% surprise

2025-11-04

$0.55

+9.1% surprise

2025-08-05

$0.46

-2.4% surprise

Healthcare Sector Comparison

Comparing FMS against 551 companies in the Healthcare sector (31 bullish, 164 neutral, 356 bearish)

P/E Ratio

11.56

This Stock

77.08

Sector Avg

-85.0% (Discount)

Return on Equity (ROE)

7.93%

This Stock

-89.58%

Sector Avg

-108.9% (Below Avg)

Profit Margin

4.98%

This Stock

-16.45%

Sector Avg

-130.3% (Weaker)

Debt to Equity

0.76

This Stock

2.7

Sector Avg

-72.0% (Less Debt)

Revenue Growth

-0.3%

This Stock

125.97%

Sector Avg

-100.2% (Slower)

Current Ratio

1.26

This Stock

4.51

Sector Avg

-72.0% (Weaker)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
FMS Fresenius Medical Care AG	BULLISH	$12.44B	11.56	7.9%	5.0%	$22.77
IONS Ionis Pharmaceuticals, Inc.	BEARISH	$12.42B	-	-70.8%	-40.4%	$75.17	Compare
MDGL Madrigal Pharmaceuticals, Inc.	NEUTRAL	$12.06B	-	-42.5%	-30.1%	$525.67	Compare
ENSG The Ensign Group, Inc.	NEUTRAL	$11.96B	34.36	16.9%	6.8%	$204.79	Compare
JAZZ Jazz Pharmaceuticals plc	NEUTRAL	$11.96B	-	-8.5%	-8.3%	$194.2	Compare

FMS Fresenius Medical Care AG

BULLISH

Mkt Cap

$12.4B

P/E

11.6

ROE

7.9%

Price

$22.77

Compare with FMS

Compare with FMS

ENSG The Ensign Group, Inc.

Compare with FMS

Compare with FMS

SEC Filings

Recent regulatory filings from the SEC EDGAR database

20-F

FORM 20-F

2026-02-24

FMS submitted its annual Form 20-F filing on February 24, 2026, which serves as the comprehensive yearly report for foreign private issuers. Due to the limited information provided, specific financial highlights and risk factors are not available for analysis.

20-F

FORM 20-F

2025-02-25

FMS submitted its annual Form 20-F filing on February 25, 2025. Specific financial highlights and risk factors were not provided in the available metadata.

Data sourced from SEC EDGAR. AI summaries generated automatically.

Past News Coverage

Recent headlines mentioning FMS from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

FMS

FMS Fresenius Medical Care AG - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

SEC Filings

Past News Coverage

Wait — Don't Miss Out!